Alerts will be sent to your verified email
Verify Email
BLISSGVS
|
Bliss GVS Pharma
|
Syncom Formulations
|
Jagsonpal Pharma
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Pharmaceutical Sector
|
|||
|
R&D as a % of Total Sales
|
2.7 % | n/a | n/a |
|
Financials
|
|||
|
5 yr Average ROE
|
6.83 % | 8.81 % | 16.01 % |
|
5yr average Equity Multiplier
|
1.3 | 1.5 | 1.27 |
|
5yr Average Asset Turnover Ratio
|
0.62 | 0.79 | 1.09 |
|
5yr Avg Net Profit Margin
|
8.7 % | 7.78 % | 12.08 % |
|
Price to Book
|
1.54 | 4.43 | 6.09 |
|
P/E
|
15.14 | 26.34 | 24.02 |
|
5yr Avg Cash Conversion Cycle
|
186.56 Days | 84.02 Days | 2.39 Days |
|
Inventory Days
|
54.35 Days | 27.61 Days | 37.29 Days |
|
Days Receivable
|
189.93 Days | 123.89 Days | 15.63 Days |
|
Days Payable
|
75.78 Days | 93.18 Days | 59.94 Days |
|
5yr Average Interest Coverage Ratio
|
14.68 | 39.83 | 66.99 |
|
5yr Avg ROCE
|
13.27 % | 12.74 % | 18.99 % |
|
5yr Avg Operating Profit Margin
|
17.03 % | 9.47 % | 13.23 % |
|
5 yr average Debt to Equity
|
0.11 | 0.2 | 0.01 |
|
5yr CAGR Net Profit
|
4.24 % | 19.56 % | 26.54 % |
|
5yr Average Return on Assets
|
5.31 % | 5.89 % | 12.71 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
35.44 % | 50.57 % | 67.65 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
0.93 % | 0.0 | -1.06 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
|
Bliss GVS Pharma
|
Syncom Formulations
|
Jagsonpal Pharma
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|